NPX372 for Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
NPX372 is an antibody drug (protein drug) that blocks a specific protein which is found to be increased on the surface of cancer cells called B7-H7 and, at the same time, binds to immune cells (T cells) through a receptor called CD3. The effect of this binding is to activate T cells to kill cancer cells with B7-H7.
In this research study we are:
* Evaluating the safety and possible effectiveness of NPX372.
* Identifying a safe and tolerable dose or doses for further study.
Participants who are treated will receive an intravenous (IV) infusion of NPX372 if their disease has not progressed, and be closely monitored by the treating physicians.
Who Is on the Research Team?
Leena Gandhi, MD, Ph.D.
Principal Investigator
NextPoint Therapeutics, Inc.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive an intravenous (IV) infusion of NPX372 and are closely monitored by the treating physicians
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- NPX372
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
NPX372 is provided in single-use 5 mg vials at 1 mg per mL and is administered as an IV infusion over 60 minutes.
Find a Clinic Near You
Who Is Running the Clinical Trial?
NextPoint Therapeutics, Inc.
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.